Recent advances in the molecular pathogenesis of hereditary recurrent fevers

Current Opinion in Allergy and Clinical Immunology

Volumn 6, Issue 6, 2006, Pages 428-433

  Masters, Seth L ^a   Lobito, Adrian A ^a   Chae, Jaejin ^a   Kastner, Daniel L ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Cryopyrin associated periodic syndromes; Familial Mediterranean fever; Hereditary recurrent fever syndromes; Hyperimmunoglobulinemia D with periodic fever syndrome; Tumor necrosis factor receptor associated periodic syndrome

Indexed keywords

INTERLEUKIN 1BETA CONVERTING ENZYME; METALLOPROTEINASE; TUMOR NECROSIS FACTOR RECEPTOR;

CARBOXY TERMINAL SEQUENCE; CLINICAL FEATURE; DISEASE ASSOCIATION; GENE MUTATION; HUMAN; MOLECULAR DYNAMICS; MOLECULAR MODEL; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BINDING; RECURRENT FEVER; REVIEW; RNA ANALYSIS;

AMINO ACID MOTIFS; ANIMALS; CARRIER PROTEINS; CASPASE 1; CYTOSKELETAL PROTEINS; FAMILIAL MEDITERRANEAN FEVER; HUMANS; METALLOPROTEASES; MUTATION; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 33750838535     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3280109b57     Document Type: Review

References (33)

1. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17:586-599.
2. Kastner DL. Hereditary periodic fever syndromes. Hematology (Am Soc Hematol Educ Program) 2005:74-81.
3. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group. Nat Genet 1999; 22:178-181.
4. Houten SM, Kuis W, Duran M, et al. Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome. Nat Genet 1999; 22:175-177.
5. Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301-305.
6. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10:417-426.
7. Mariathasan S, Weiss DS, Newild-typeon K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440:228-232. Highlights the requirement of NALP3 in the mouse for responses to toxins and ATP.
8. Sutterwala FS, Ogura Y, Szczepanik M, et al. Critical role for NALP3/CIAS1/cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006; 24:317-327. Highlights the requirement of NALP3 in the mouse for responses to TLR stimuli and ATP, and contact hypersensititvity to TNP-CL.
9. Perregaux D, Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin: evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 1994; 269:15195-15203.
10. Kanneganti TD, Ozoren N, Body-Malapel M, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006; 440:233-236. Highlights the requirement of NALP3 in the mouse for responses to bacterial RNA and several antiviral compounds.
11. Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440:237-241. Shows that NALP3 is an important mediator of inflammation induced in a mouse model of gout.
12. Martinon F, Agostini L, Meylan E, Tschopp J. Identification of bacterial muramyl dipeptide as activator of the NALP3/cryopyrin inflammasome. Curr Biol 2004; 14:1929-1934.
13. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997; 90:797-807.
14. A candidate gene for familial Mediterranean fever. The French FMF Consortium. Nat Genet 1997; 17:25-31.
15. Kastner DL. Familial Mediterranean fever: the genetics of inflammation. Hosp Pract (Minneap) 1998; 33:131-134; 139-140, 143-146 passim.
16. Mansfield E, Chae JJ, Komarow HD, et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 2001; 98:851-859.
17. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1β production. Proc Natl Acad Sci U S A 2006; 103:9982-9987. Documents the direct interaction of the pyrin B30.2 domain with caspase-1, and presents a model for the structure of this complex.
18. Grutter C, Briand C, Capitani G, et al. Structure of the PRYSPRY-domain: implications for autoinflammatory diseases. FEBS Lett 2006; 580:99-106. One of three primary publications to describe the structure of the B30.2 domain.
19. Masters SL, Yao S, Willson TA, et al. The SPRY domain of SSB-2 adopts a novel fold that presents conserved Par-4-binding residues. Nat Struct Mol Biol 2006; 13:77-84. One of three primary publications to describe the structure of the B30.2 domain.
20. Woo JS, Imm JH, Min CK, et al. Structural and functional insights into the B302/SPRY domain. EMBO J 2006; 25:1353-1363. One of three primary publications to describe the structure of the B30.2 domain.
21. Yu JW, Wu J, Zhang Z, et al. Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ 2006; 13:236-249. Outlines a proinflammatory role for pyrin when overexpressed in 293T cells.
22. Chae JJ, Komarow HD, Cheng J, et al. Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol Cell 2003; 11:591-604.
23. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999; 97:133-144.
24. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10:45-65.
25. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46:3340-3348.
26. Engelmann H, Aderka D, Rubinstein M, et al. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264:11974-11980.
27. Huggins ML, Radford PM, McIntosh RS, et al. Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum 2004; 50:2651-2659.
28. Todd I, Radford PM, Draper-Morgan KA, et al. Mutant forms of tumour necrosis factor receptor I that occur in TNF-receptor-associated periodic syndrome retain signalling functions but show abnormal behaviour. Immunology 2004; 113:65-79.
29. Siebert S, Fielding CA, Williams BD, Brennan P. Mutation of the extracellular domain of tumour necrosis factor receptor 1 causes reduced NF-kappaB activation due to decreased surface expression. FEBS Lett 2005; 579:5193-5198.
30. Lobito AA, Kimberley FC, Muppidi JR, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in the TNFR1 associated periodic fever syndrome (TRAPS). Blood 2006; 108:1320-1327. Documents misfolding of TNFR1 in vitro and in vivo, and colocalization of the misfolded protein with endoplasmic reticulum markers.
31. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006; 355:581-592. Inhibition of the IL-1β pathway is an excellent treatment for the most severe cryopyrin-associated periodic fever syndrome.
32. Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med 2004; 117:208-210.
33. Takada K, Aksentijevich I, Mahadevan V, et al. Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 2003; 48:2645-2651.